Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Alexandrosz Czira, Gema Requena, Victoria Banks, Robert Wood, Theo Tritton, Catherine M Castillo, Jie Yeap, Rosie Wild, Chris Compton, Kieran J Rothnie, Felix Herth, Jennifer K Quint & Afisi S Ismaila. (2023) Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 643-659.
Read now
Read now
Pei-An Liao, Sheng-Wei Pan, Chun-Yu Chen, Chung-Yeh Deng & Yaa-Hui Dong. (2023) Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 553-563.
Read now
Read now
Pik-Qi Chin, Chau-Chyun Sheu, Jong-Rung Tsai, Hsu-Liang Chang, Li-Yao Lee & Chung-Yu Chen. (2022) Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator. Patient Preference and Adherence 16, pages 875-886.
Read now
Read now
Ravi Kalhan, David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Sean Dale MacKnight & Beth Hahn. (2021) Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1149-1161.
Read now
Read now
Gema Requena, Daniel Dedman, Jennifer K Quint, Rebecca E Ghosh, Rachael Williams & Jeanne M Pimenta. (2021) The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 629-642.
Read now
Read now
Leah B Sansbury, Chanchal Bains, David A Lipson, Afisi S Ismaila & Sarah H Landis. (2021) Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1255-1264.
Read now
Read now
Xiaoli Niu, Victoria Divino, Sanjay Sharma, Mitch Dekoven, Vamshi Ruthwik Anupindi & Carole Dembek. (2021) Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with nebulized glycopyrrolate in the USA: a real-world data analysis. Journal of Medical Economics 24:1, pages 1-9.
Read now
Read now
Chad Moretz, Beth Hahn, John White, Alyssa Goolsby Hunter, Breanna Essoi, Caitlin Elliott & Riju Ray. (2020) Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2715-2725.
Read now
Read now
Chad Moretz, Ashley L Cole, George Mu, Benjamin Wu, Amy Guisinger, Yunhao Liu, Beth Hahn & Lee Baylis. (2020) Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2207-2215.
Read now
Read now
Rongchang Chen, Yue Gao, He Wang, Hongyan Shang & Jianwei Xuan. (2020) Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 963-971.
Read now
Read now
Articles from other publishers (7)
Mònica Monteagudo, Alexa Nuñez, Miriam Barrecheguren & Marc Miravitlles. (2022) Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study. Archivos de Bronconeumología 58:10, pages 699-707.
Crossref
Crossref
Mario Cazzola, Clive Page, Paola Rogliani, Luigino Calzetta & Maria Gabriella Matera. (2022) Dual bronchodilation for the treatment of COPD: From bench to bedside. British Journal of Clinical Pharmacology 88:8, pages 3657-3673.
Crossref
Crossref
Chloe I. Bloom, Jukka Montonen, Olaf Jöns, Elizabeth M. Garry & Surya P. Bhatt. (2022) Treatment Transitions in Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases. Pulmonary Therapy 8:1, pages 75-93.
Crossref
Crossref
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Malena Mahendran & Beth Hahn. (2021) Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
Swetha R PalliBin XieBenjamin ChastekCaitlin A ElliottLindsay G S Bengtson. (2021) Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies. Journal of Managed Care & Specialty Pharmacy 27:7, pages 810-824.
Crossref
Crossref
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Sean D. MacKnight & Beth Hahn. (2021) Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease. Pulmonary Therapy 7:1, pages 203-219.
Crossref
Crossref
Jennifer K. Quint, Jukka Montonen, Daina B. Esposito, Xintong He, Leslie Koerner, Laura Wallace, Alberto de la Hoz & Marc Miravitlles. (2021) Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database. Advances in Therapy 38:5, pages 2249-2270.
Crossref
Crossref